SCHEMBL349880

SCHEMBL349880

CCOC(=O)Cc1ccc(OC)c(Oc2ccc(N)cc2C(S)c2nnc(C)s2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.39
MAPT P10636 3/20 0.38
L3MBTL1 Q9Y468 2/20 0.37
ABL1 P00519 1/20 0.37
RIN1 Q13671 1/20 0.37
KLK7 P49862 1/20 0.36
GAA P10253 2/20 0.36
ATM Q13315 1/20 0.36
DRD2 P14416 1/20 0.36
SMN1; SMN2 Q16637 4/20 0.35
ALDH1A1 P00352 3/20 0.35
KDM4E B2RXH2 2/20 0.35
HPGD P15428 2/20 0.35
CYP2C19 P33261 2/20 0.35
MAPK1 P28482 2/20 0.35
HSD17B10 Q99714 1/20 0.35
SHMT2 P34897 1/20 0.35
TSHR P16473 1/20 0.35
MAPK10 P53779 1/20 0.35
CTSD P07339 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL347220 0.86 LMNA (0.40) LMNAMAPTSMN1; SMN2ALDH1A1KDM4E
SCHEMBL348213 0.82 LMNA (0.44) LMNAMAPTGAASMN1; SMN2ALDH1A1
SCHEMBL350031 0.82 PTGDR2 (0.41) LMNAMAPTL3MBTL1ABL1RIN1
SCHEMBL349881 0.78 ALDH1A1 (0.52) LMNAMAPTSMN1; SMN2ALDH1A1KDM4E
SCHEMBL13521900 0.76 L3MBTL1 (0.41) LMNAMAPTL3MBTL1ABL1RIN1
SCHEMBL349203 0.72 CYP3A4 (0.40) LMNAMAPTL3MBTL1ABL1RIN1
SCHEMBL908271 0.71 ABL1 (0.59) LMNAMAPTL3MBTL1ABL1RIN1
SCHEMBL1011312 0.70 PKM (0.40) MAPTL3MBTL1ABL1RIN1GAA
SCHEMBL349119 0.70 CYP3A4 (0.55) LMNAMAPTL3MBTL1ABL1RIN1
SCHEMBL13594698 0.70 ALDH1A1 (0.56) LMNAMAPTL3MBTL1ABL1RIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8247602-B2 Antagonists of prostaglandin D2 receptors PANMIRA PHARMACEUTICALS, LLC (US) 2012-08-21 US disclosed
US-20120016029-A1 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS PANMIRA PHARMACEUTICALS, LLC (US) 2012-01-19 US disclosed
US-8071807-B2 Antagonists of prostaglandin D2 receptors PANMIRA PHARMACEUTICALS, LLC (US) 2011-12-06 US disclosed
US-20110190227-A1 Antagonists of Prostaglandin D2 Receptors AMIRA PHARMACEUTICALS, INC. (US) 2011-08-04 US disclosed
US-20110144160-A1 Antagonists of Prostaglandin D2 Receptors AMIRA PHARMACEUTICALS, INC. (US) 2011-06-16 US disclosed
EP-2307362-A2 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS Amira Pharmaceuticals, Inc. (US) 2011-04-13 EP disclosed
US-20100004331-A1 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2010-01-07 US disclosed
WO-2010003120-A2 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2010-01-07 WO disclosed
WO-2010003127-A2 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS AMIRA PHARMACEUTICALS, INC. (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120016029-A1 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS PTGDR, PTGDR2, PTGER2 LMNA 2277/4885MAPT 4847/4885L3MBTL1 4068/4885
US-20100004331-A1 ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS PTGDR, PTGDR2, PTGER2 LMNA 2277/4885MAPT 4847/4885L3MBTL1 4068/4885
US-20110144160-A1 Antagonists of Prostaglandin D2 Receptors PTGDR, PTGDR2, PTGER2 LMNA 2277/4885MAPT 4847/4885L3MBTL1 4068/4885
US-20110190227-A1 Antagonists of Prostaglandin D2 Receptors PTGDR, PTGDR2, PTGER2 LMNA 2161/4885MAPT 4843/4885L3MBTL1 4395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.